These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

579 related items for PubMed ID: 9708413

  • 1. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.
    Bellman PC.
    AIDS; 1998 Jul 30; 12(11):1333-40. PubMed ID: 9708413
    [Abstract] [Full Text] [Related]

  • 2. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
    Kuritzkes DR, Bassett RL, Johnson VA, Marschner IC, Eron JJ, Sommadossi JP, Acosta EP, Murphy RL, Fife K, Wood K, Bell D, Martinez A, Pettinelli CB.
    AIDS; 2000 Jul 28; 14(11):1553-61. PubMed ID: 10983642
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
    Joly V, Flandre P, Meiffredy V, Brun-Vezinet F, Gastaut JA, Goujard C, Remy G, Descamps D, Ruffault A, Certain A, Aboulker JP, Yeni P, Novavir Study Group.
    Antimicrob Agents Chemother; 2002 Jun 28; 46(6):1906-13. PubMed ID: 12019107
    [Abstract] [Full Text] [Related]

  • 9. Delavirdine: a review of its use in HIV infection.
    Scott LJ, Perry CM.
    Drugs; 2000 Dec 28; 60(6):1411-44. PubMed ID: 11152019
    [Abstract] [Full Text] [Related]

  • 10. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
    Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, Sayer D, Emery S, Cooper DA.
    AIDS; 2000 Jun 16; 14(9):1171-80. PubMed ID: 10894281
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
    Cohen Stuart JW, Schuurman R, Burger DM, Koopmans PP, Sprenger HG, Juttmann JR, Richter C, Meenhorst PL, Hoetelmans RM, Kroon FP, Bravenboer B, Hamann D, Boucher CA, Borleffs JC.
    AIDS; 1999 May 07; 13(7):F53-8. PubMed ID: 10357371
    [Abstract] [Full Text] [Related]

  • 13. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
    Eron JJ, Yetzer ES, Ruane PJ, Becker S, Sawyer GA, Fisher RL, Tolson JM, Shaefer MS.
    AIDS; 2000 Apr 14; 14(6):671-81. PubMed ID: 10807190
    [Abstract] [Full Text] [Related]

  • 14. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar 10; 14(4):367-74. PubMed ID: 10770538
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA.
    N Engl J Med; 1997 Sep 11; 337(11):725-33. PubMed ID: 9287227
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P.
    Antivir Ther; 2005 Sep 11; 10(8):911-6. PubMed ID: 16430196
    [Abstract] [Full Text] [Related]

  • 18. Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus.
    Wintergerst U, Hoffmann F, Sölder B, Notheis G, Petropoulou T, Eberle J, Gürtler L, Belohradsky BH.
    Pediatr Infect Dis J; 1998 Jun 11; 17(6):495-9. PubMed ID: 9655541
    [Abstract] [Full Text] [Related]

  • 19. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Ruef C, Zimmerli S.
    AIDS Res Hum Retroviruses; 1999 Dec 10; 15(18):1631-8. PubMed ID: 10606086
    [Abstract] [Full Text] [Related]

  • 20. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.
    García F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.
    J Acquir Immune Defic Syndr; 2000 Sep 01; 25(1):26-35. PubMed ID: 11064501
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.